Edition:
United States

Aap Implantate AG (AAQG.DE)

AAQG.DE on Xetra

1.47EUR
18 Aug 2017
Change (% chg)

€-0.02 (-1.61%)
Prev Close
€1.49
Open
€1.48
Day's High
€1.48
Day's Low
€1.46
Volume
2,391
Avg. Vol
41,184
52-wk High
€1.65
52-wk Low
€1.05

Latest Key Developments (Source: Significant Developments)

aap implantate: exploration of strategic alternatives
Monday, 14 Aug 2017 04:43am EDT 

Aug 14 (Reuters) - AAP IMPLANTATE AG ::ANNOUNCES EXPLORATION OF STRATEGIC ALTERNATIVES TO CREATE MORE VALUE.‍THERE IS NO SET TIME TABLE FOR THIS PROCESS OF EXPLORING STRATEGIC ALTERNATIVES​.IS EXPLORING CO-DEVELOPMENT-/LICENSE AGREEMENTS, JOINT VENTURE AGREEMENTS TO CORPORATE TRANSACTIONS (E.G. MERGER, SHARE OR ASSET DEAL, CARVE OUT).  Full Article

Aap Implantate announces public share buyback offer
Thursday, 15 Jun 2017 04:54am EDT 

June 15 (Reuters) - AAP IMPLANTATE AG ::PUBLIC SHARE BUYBACK OFFER.TO PURCHASE UP TO 2.25 MILLION SHARES OF COMPANY BY MEANS OF VOLUNTARY PUBLIC SHARE BUYBACK OFFER AGAINST CASH PAYMENT OF EUR 1.52 PER NO-PAR VALUE SHARE FOR MAX TOTAL PURCHASE PRICE OF UP TO EUR 3.5 MILLION.  Full Article

aap Implantate says plans share buyback
Monday, 8 May 2017 04:28am EDT 

May 8 (Reuters) - AAP IMPLANTATE AG ::MANAGEMENT BOARD AND SUPERVISORY BOARD PLAN SHARE BUYBACK TO PARTIALLY DISTRIBUTE PROCEEDS FROM THE SALE OF AAP BIOMATERIALS GMBH.IT IS INTENDED WITHIN SHARE BUYBACK TO PURCHASE UP TO 2.4 MILLION SHARES OF COMPANY FROM SHAREHOLDERS FOR A MAXIMUM TOTAL PURCHASE PRICE (INCLUDING INCIDENTAL COSTS) OF UP TO EUR 3.5 MILLION.BASED ON CURRENT SHARE PRICE LEVEL OF AAP SHARE IT IS INTENDED WITHIN SHARE BUYBACK TO PURCHASE UP TO 2.4 MILLION SHARES OF COMPANY FROM SHAREHOLDERS FOR A MAXIMUM TOTAL PURCHASE PRICE OF UP TO EUR 3.5 MILLION.AGAINST BACKGROUND OF INTENDED SHARE BUYBACK MANAGEMENT BOARD AND SUPERVISORY BOARD WILL NEITHER PROPOSE A DIVIDEND PAYMENT NOR A CAPITAL DECREASE TO ANNUAL GENERAL MEETING TAKING PLACE ON 16 JUNE 2017.  Full Article

aap Implantate Q1 sales up 23 pct at 3.1 million euros
Monday, 24 Apr 2017 04:35am EDT 

April 24 (Reuters) - aap Implantate AG ::30 pct sales growth in trauma in the first quarter of 2017.Increased total sales in Q1 of 2017 in comparison to first three months of last year by 23 pct to 3.1 million euros (Q1/2016: 2.5 million euros).  Full Article

aap Implantate concludes distribution agreement for LOQTEQ radius system
Friday, 21 Apr 2017 04:27am EDT 

April 21 (Reuters) - aap Implantate AG ::Concludes distribution agreement for LOQTEQ radius system with US medical technology company.  Full Article

aap Implantate 2016 sales and EBITDA below guidance
Tuesday, 21 Mar 2017 09:58am EDT 

aap Implantate AG : Sales by 514,000 euros ($555,993.80) and EBITDA by 450,000 euros slightly below guidance for financial year 2016 due to failure of distributor to fulfil contractual duties . Announces that in course of drawing up annual financial statements for 2016 management board decided as a precautionary measure to revoke an initial sale with a distribution partner invoiced in financial year . Reason is a delayed payment of contractual due purchase price .In continued operation in financial year 2016 sales are at 10.5 million euros and EBITDA at -7.9 million euros and thereby slightly below current guidance.  Full Article

aap Implantate Q4 sales stable at 2.4 million euros
Wednesday, 1 Mar 2017 02:28am EST 

aap Implantate AG : Said on Tuesday achieved prelim sales of 2.4 million euros ($2.53 million) in the continued operation in the fourth quarter of 2016 (Q4/2015: 2.4 million euros) . Sales of 11.2 million euros in the continued operation in financial year 2016 as a whole (FY/2015: 12.3 million euros) .Forecast for FY/2017: sales between 10.0 million euros and 13.0 million euros and EBITDA between -6.5 million euros and 4.5 million euros; dynamic development expected from the second half of the year.  Full Article

Aap Implantate will not achieve previous FY 2016 sales and EBITDA forecast for continued operation
Thursday, 15 Dec 2016 04:39am EST 

Aap Implantate AG : aap updates forecast for financial year 2016 due to delays in sales development in various markets . Announces that it will not achieve previous sales and EBITDA forecast for financial year 2016 for continued operation . Adjusts its forecast for financial year 2016 for continued operation and now anticipates sales between 11.0 million euros and 12.1 million euros ($12.71 million)as well as an EBITDA of -7.5 million to -7.0 million euros . For 2016 EBITDA of group (continued and discontinued operation including deconsolidation profit from sale of aap biomaterials gmbh) company anticipates a value of between 16.5 million and 17.0 million euros . Management board aims at a ce approval and closing of a license deal in financial year 2017 which will have visible influence on financial figures .Reasons for this adjustment are delays in sales development in various markets leading to a sales shift in financial year 2017.  Full Article

Aap Implantate post Q2 EBITDA loss from continued oprations of 1.4 mln euros
Friday, 12 Aug 2016 11:27am EDT 

Aap Implantate AG : In the continued operation sales and EBITDA in Q2/2016 at 3.4 million euros ($3.80 million) (guidance: 2.5 million euros to 3.5 million euros) and -1.4 million euros (guidance: -2.5 million euros to -1.5 million euros) respectively . In Q3 of 2016, aap aims to achieve further progress in its strategy implementation .For Q3 of 2016, aap is expecting for continued operation sales to range between 2.5 million euros and 4.0 million euros and an EBITDA of -2.0 million euros to -1.2 million euros.  Full Article

Aap Implantate now sees FY EBITDA of 18.1 - 19.7 million euros
Wednesday, 10 Aug 2016 03:42am EDT 

Aap Implantate AG : Deconsolidation profit from the sale of Aap Biomaterials GmbH leads to an increase of 2016 EBITDA forecast for the group . Sees FY 2016 EBITDA of group of between 18.1 million and 19.7 million euros (previously between 14.1 million and 15.7 million euros) .Now sees FY EBITDA of continued operation of between -5.9 million and -4.3 million euros.  Full Article

BRIEF-Aap Implantate: resolution on capital reduction

* ‍AFTER IMPLEMENTATION OF CAPITAL REDUCTION AAP IMPLANTATE AG'S SHARE CAPITAL AMOUNTS TO EUR 28.6 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)